Chiesi Returns To Respiratory Roots With Affibody Pact
Upfront And Milestone Payments up to $214m
A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.
You may also be interested in...
The Italian drugmaker has reported strong sales for 2022 driven by its respiratory drugs but this year will see a more prominent contribution from its rare disease offerings.
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Janssen’s Akeega is among the latest drugs that the European Medicines Agency says should be approved for use in the EU. Meanwhile, MSD/Ridgeback Biotherapeutics plan to appeal the agency’s rejection of their COVID-19 treatment.